SEAL1 myCAF solid-cancer program
preclinicalresearch program · high · Fri Apr 17 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Target the SEAL1 long non-coding RNA to reduce pro-tumorigenic myofibroblast-like cancer-associated fibroblast cell states and improve solid-cancer therapeutic response.
ASO-mediated targeting of SEAL1 and murine Seal1; CRISPRi/ASO comparator targeting of LRRC15; patient-derived myCAF models and xenograft co-injection in vivo model.
AACR 2026 abstract reported SEAL1 as a promising therapeutic target for solid cancers.
SEAL1 targeting reduced myCAF identity in vitro and reduced tumor volume in a xenograft co-injection model; LRRC15 targeting had no effect on the disease-driving myCAF state or tumor volume.
Cardiac fibrosis and remodeling control program
preclinicalresearch program · low · Tue Dec 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Control cardiac fibrosis and remodeling after cardiac injury.
Methods and compositions for controlling cardiac fibrosis and remodeling described in a University of Lausanne patent listing inventors Samir Ounzain and Thierry Pedrazzini.
US patent family listed as granted, with US12491205B2 grant date shown as 2025-12-09.
WISP2 super-enhancer-associated RNA modulation program
preclinicaldrug program · medium · Thu May 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Modulate WISP2 super-enhancer-associated RNA for therapeutic use.
Compositions and methods for modulating WISP2 super-enhancer-associated RNA, as described in HAYA Therapeutics patent filings.
Patent application WO2025056973A3 published on 2025-05-15; application filed by Haya Therapeutics SA on 2024-09-13.
FIMICS cardiovascular lncRNA panel
exploratorybiomarker · medium · Sun Jan 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Identify cardiac-enriched and disease-associated long non-coding RNAs as biomarkers for cardiovascular conditions.
Deep RNA sequencing and quantitative PCR to identify lncRNAs differentially expressed between failing and non-failing hearts, followed by evaluation in blood samples from myocarditis and acute myocardial infarction patients.
2023 Heliyon publication described a panel of 2,906 lncRNAs named FIMICS.
Expression of FIMICS lncRNAs in blood samples differentiated patients with myocarditis and acute myocardial infarction.
FIMICS cardiovascular lncRNA biomarker panel
exploratorybiomarker · medium
Identify cardiac-enriched long non-coding RNAs that can provide insight into cardiovascular pathologies and support diagnosis, monitoring, or prognosis.
Deep RNA sequencing and quantitative PCR to identify lncRNAs differentially expressed between failing and non-failing hearts, with evaluation in blood samples from myocarditis and acute myocardial infarction patients.
Published panel of 2906 cardiac-enriched or disease-associated lncRNAs.
Expression of lncRNAs in blood samples differentiated patients with myocarditis and acute myocardial infarction.
HTX-001
undiscloseddrug program · medium
Investigational precision cellular reprogramming therapy for cardiac fibrosis.
RNA-guided therapy targeting disease-driving cell states associated with cardiac fibrosis.
First cohort dosed in a Phase 1 clinical trial.
Regulatory genome lncRNA discovery platform
undisclosedplatform · high
Decode the regulatory genome to identify non-coding RNAs that causally drive disease and enable programmable RNA medicines that reprogram disease-driving cell states.
Multimodal functional genomics combined with proprietary computational tools to identify causal non-coding RNA targets.
Platform described as the basis for HAYA's pipeline and for expansion beyond cardiac disease into oncology.
RNA-guided regulatory genome platform
exploratoryplatform · high
Decode the regulatory genome to identify non-coding RNAs that causally drive disease and use them to reprogram disease-driving cell states.
Multimodal functional genomics combined with proprietary computational tools to identify causal non-coding RNA targets and design programmable RNA medicines.
Company describes the platform as the basis for HAYA's RNA-guided therapies.
SEAL1 myCAF solid cancer program
preclinicalresearch program · medium
Target the SEAL1 long non-coding RNA to reduce pro-tumorigenic myofibroblast-like cancer-associated fibroblast cell states in solid cancers and potentially improve response to combination treatments including immunotherapy.
Identification of SEAL1 in pan-cancer myCAF regulatory networks, followed by antisense oligonucleotide targeting of SEAL1 or murine Seal1 in cellular models and xenograft co-injection models.
AACR 2026 abstract reported SEAL1 as a promising therapeutic target for solid cancers.
ASO-mediated targeting reduced myCAF identity in vitro; SEAL1 targeting in patient-derived myCAFs reduced tumor volume in a xenograft co-injection model, while LRRC15 targeting had no effect.
